Screener
Corvus Pharmaceuticals CRVS Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Loss from operations | (14,877) | (9,922) |
| Interest income and other expense, net | 1,784 | 525 |
| Change in fair value of warrant liability | — | 25,129 |
| Loss before equity method investment | (13,093) | 15,732 |
| Loss from equity method investment | (599) | (539) |
| Net (loss) income | $(13,692) | $15,193 |
| Net (loss) income per share, basic | $(0.15) | $0.21 |
| Net loss per share, diluted | $(0.15) | $(0.13) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's pre-tax income?
- Corvus Pharmaceuticals (CRVS) reported pre-tax income of -$13.09M in Q1 2026.
- How has Corvus Pharmaceuticals's pre-tax income changed year-over-year?
- Corvus Pharmaceuticals's pre-tax income decreased by 183.2% year-over-year, from $15.73M to -$13.09M.
- What is the long-term trend for Corvus Pharmaceuticals's pre-tax income?
- Over 3 years (2022 to 2025), Corvus Pharmaceuticals's pre-tax income has grown at a -24.8% compound annual growth rate (CAGR), from -$31.3M to -$13.33M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Corvus Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude